prikaz prve stranice dokumenta Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
  Preuzmi
PDF 2.44 MB
Znanstveni rad - Izvorni znanstveni rad
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
Frontiers in Immunology, 13 (2022); 818325. https://doi.org/10.3389/fimmu.2022.818325
Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Maglione, Alessandro; Taverna, Daniela; Novelli, Francesco; Cocco, Eleonora; Vladić, Anton; Habek, Mario; Adamec, Ivan; Annovazzi, Pietro Osvaldo Luigi; Horakova, Dana; Clerico, Marinella

Citirajte ovaj rad

Rolla, S., De Mercanti, S. F., Bardina, V., Maglione, A., Taverna, D., Novelli, F. ... Clerico, M. (2022). Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 13.. doi: 10.3389/fimmu.2022.818325

Rolla, Simona, et al. "Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up." Frontiers in Immunology, vol. 13, 2022. https://doi.org/10.3389/fimmu.2022.818325

Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, Alessandro Maglione, Daniela Taverna, Francesco Novelli, Eleonora Cocco, et al. "Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up." Frontiers in Immunology 13 (2022). https://doi.org/10.3389/fimmu.2022.818325

Rolla, S., et al. (2022) 'Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up', Frontiers in Immunology, 13. doi: 10.3389/fimmu.2022.818325

Rolla S, De Mercanti SF, Bardina V, Maglione A, Taverna D, Novelli F, i sur.. Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology [Internet]. 28.02.2022. [pristupljeno 11.04.2024.];13. doi: 10.3389/fimmu.2022.818325

S. Rolla, et al., "Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up", Frontiers in Immunology, vol. 13, Veljača 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:992905. [Citirano: 11.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:992905
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
AutorSimona Rolla
AutorStefania Federica De Mercanti
AutorValentina Bardina
AutorAlessandro Maglione
AutorDaniela Taverna
AutorFrancesco Novelli
AutorEleonora Cocco
AutorAnton Vladić
AutorMario Habek
AutorIvan Adamec
AutorPietro Osvaldo Luigi Annovazzi
AutorDana Horakova
AutorMarinella Clerico
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA NEUROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Introduction: Alemtuzumab is highly effective in the treatment of patients with relapsing multiple sclerosis (PwRMS) and selectively targets the CD52 antigen, with a consequent profound lymphopenia, particularly of CD4+ T lymphocytes. However, the immunological basis of its long-term efficacy has not been clearly elucidated. ----- Methods: We followed up 29 alemtuzumab-treated RMS patients over a period of 72 months and studied the immunological reconstitution of their CD4+ T cell subsets by means of phenotypic and functional analysis and through mRNA-related molecule expression, comparing them to healthy subject (HS) values (rate 2:1). ----- Results: In patients receiving only two-course alemtuzumab, the percentage of CD4+ lymphocytes decreased and returned to basal levels only at month 48. Immune reconstitution of the CD4+ subsets was characterized by a significant increase (p < 0.001) in Treg cell percentage at month 24, when compared to baseline, and was accompanied by restoration of the Treg suppressor function that increased within a range from 2- to 6.5-fold compared to baseline and that persisted through to the end of the follow-up. Furthermore, a significant decrease in self-reactive myelin basic protein-specific Th17 (p < 0.0001) and Th1 (p < 0.05) cells reaching HS values was observed starting from month 12. There was a change in mRNA of cytokines, chemokines, and transcriptional factors related to Th17, Th1, and Treg cell subset changes, consequently suggesting a shift toward immunoregulation and a reduction of T cell recruitment to the central nervous system. ----- Conclusions: These data provide further insight into the mechanism that could contribute to the long-term 6-year persistence of the clinical effect of alemtuzumab on RMS disease activity.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Immunology
Brojčani podacivol. 13, 818325
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2022.818325
URN:NBNurn:nbn:hr:105:992905
Datum objave publikacije2022-02-28
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fimmu.2022.818325/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-09-30 09:40:14